MARY SCHEXNAYDRE: Open Payments
NPI 1942794367 · NEW ORLEANS, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,325 in 45 payments from 8 companies in 2025. Trend: 2023 $1,177 · 2024 $565 · 2025 $1,325
Food & beverage: $1,325
| Company | Payments | Amount |
|---|---|---|
| Janssen Pharmaceuticals, Inc | 7 | $266 |
| E.R. Squibb & Sons, L.L.C. | 10 | $222 |
| Teva Pharmaceuticals USA, Inc. | 6 | $222 |
| Alkermes, Inc. | 10 | $218 |
| Otsuka America Pharmaceutical, Inc. | 5 | $186 |
| Neurocrine BioSciences, Inc. | 5 | $163 |
| Vanda Pharmaceuticals Inc. | 1 | $33 |
| Luye Pharma (USA) Ltd. | 1 | $15 |
Products named: COBENFY, ARISTADA, SPRAVATO, UZEDY, INGREZZA, REXULTI, INVEGA, AUSTEDO XR.
Industry payments across LA — which companies pay providers there.
